Key Takeaways
- CPOM diligence is a separate exercise from standard M&A diligence. Financials and contracts do not surface the structural defects that make a California treatment business un-transferrable in the form the seller presents.
- Sellers most often obscure four things: the absence of a physician-owned professional corporation, a paper medical director, direct patient billing by a non-licensee entity, and fee-splitting arrangements that violate B&P § 650.
- The Attorney General’s June 2026 Carbon Health settlement identified specific MSA arrangements the AG considers problematic — assignable option agreements, exclusive above-market financing, and comprehensive MSO operational control. Buyers now have a benchmark to check target arrangements against.
- Some red flags are dealbreakers. Others are fixable, but only if the buyer identifies them before closing and structures the deal to address them.
Non-licensee buyers of California treatment businesses — med spas, IV hydration clinics, hyperbaric facilities, ketamine clinics, GLP-1 weight-loss practices, wellness centers, do standard M&A diligence: financials, contracts, employment, tax, litigation. Standard diligence is necessary and not sufficient. In California, the deal also needs Corporate Practice of Medicine diligence: an audit of the target’s compliance with the doctrine that governs who can lawfully own and operate a practice that treats patients. CPOM diligence is where sellers most often have something to hide, where the buyer’s downstream exposure most often gets manufactured, and where a bad target can be identified before the buyer has spent months and dollars on a deal that cannot compliantly close.
This is a diagnostic tool. Work through it before the LOI is signed. If more than one or two red flags come up, the deal is not necessarily dead — but the structure has to be built to fix them, not to inherit them.
The Twelve Red Flags
1. The seller operates through an LLC that treats patients
Why it matters. Cal. Corp. Code § 17701.04(e) prohibits a California LLC from rendering professional services. If the target operates through an LLC and the LLC has been billing patients for medical services (injectables, laser, IV with legend drugs, hyperbaric treatment for medical indications, controlled-substance infusions, prescription weight-loss drugs), the seller has been operating out of compliance. This is common in the med spa and IV hydration segments and is often the first defect a buyer needs to identify.
Diligence question. What entity holds the target’s business license, employs the clinical staff, and appears on patient billing statements?
Diligence signal. If the LLC is doing all three, this is a red flag. Buying and continuing to operate through the seller’s LLC extends the seller’s historical exposure to the buyer and adds new post-closing exposure to the buyer’s own operation.
Fix path. The compliant path is to close as an asset purchase (not a purchase of the LLC), form a new physician-owned professional corporation to acquire the clinical assets, and recast the surviving entity (either the seller’s LLC or the buyer’s new MSO) as the Management Services Organization providing non-clinical services to the PC under an MSA. Historical exposure remains with the seller and needs to be addressed in the deal documents.
2. There is no physician-owned professional corporation
Why it matters. California treatment businesses have to be delivered by a physician-owned professional corporation formed under Cal. Corp. Code § 13401.5. If the target has no PC — only the LLC or non-physician corporation the seller has been using as the operating entity — the target has no compliant clinical vehicle. The seller may not perceive this as a defect; many operators built their business without understanding they needed one.
Diligence question. Where are the target’s clinical services legally rendered? What is the exact name of the professional corporation, and who are its shareholders?
Diligence signal. “There isn’t one” is the red flag. So is “we have an MSO” without any accompanying PC — an MSO with no PC to manage is not a compliant structure; it is a non-clinical entity that has been treating patients.
Fix path. The physician-partner forms a new PC before closing. The clinical assets transfer into the new PC. The buyer’s MSO takes the non-clinical assets. The deal timeline needs to accommodate PC formation, which typically takes weeks — including the Medical Board Fictitious Name Permit under B&P § 2415 if the practice operates under a brand name.
3. Paper medical director
Why it matters. A medical director is a physician who provides clinical oversight to a practice that delivers services within the physician’s scope. In a compliant med spa, IV clinic, or similar practice, the medical director actually performs (or supervises) good-faith exams before treatment, reviews charts, develops and approves standardized procedures under 16 CCR § 1474, is reachable during procedures, supervises delegated clinical work, and manages clinical incidents. A paper medical director is a physician who appears on the target’s paperwork but does not do any of that. Paper medical director arrangements have been a frequent focus of California Medical Board and Attorney General enforcement.
Diligence question. What does the medical director actually do? How many good-faith exams did the medical director personally conduct or supervise last quarter? When was the standardized procedures manual last reviewed and signed by the medical director? What is the medical director’s actual physical or virtual presence at the practice, and what compensation reflects that presence?
Diligence signal. “The medical director signs off on the protocols” without more, “the medical director is available if we need them,” “the medical director’s compensation is a flat monthly fee unrelated to hours or activity” — these are signals that the medical director arrangement may not survive scrutiny.
Fix path. The buyer’s structure needs an actual, engaged medical director — often the same physician who holds the PC. Compensation should be tied to services actually performed. The standardized procedures need to be reviewed and updated. The good-faith exam workflow needs to be reworked to reflect the physician’s actual role.
4. The seller says “just take over my LLC”
Why it matters. This is a common seller pitch, and it collapses on inspection. See red flag #1. An LLC cannot render medical services in California, and the target’s LLC has been doing so if it has been billing patients for clinical care. Taking over the LLC and continuing operations extends the seller’s exposure to the buyer.
Diligence question. What exactly is the seller proposing to transfer, and what will the buyer’s post-closing operating structure look like?
Diligence signal. A seller who is committed to an LLC-transfer structure and resistant to an asset purchase with a bifurcated clinical/non-clinical transfer may not have counsel who understands the CPOM constraint, or may be trying to move the historical exposure onto the buyer.
Fix path. Insist on an asset purchase structure. If the seller will not accommodate, the deal may not be worth the risk profile. Buyer’s counsel should be involved before the LOI is signed to preserve the right structure.
5. No good-faith exam workflow
Why it matters. California requires a physician (or, in appropriate scope, an NP or PA) to conduct a good-faith prior examination of a patient before prescribing or administering treatment that constitutes the practice of medicine. This includes Botox and filler, laser treatment, IV therapy with legend drugs, and prescription medications for weight loss or hormone replacement. A good-faith exam is a substantive clinical encounter — history, examination, review of any indicated diagnostic information, clinical judgment on indication and contraindication, and documented decision-making. A symptom questionnaire and a rubber-stamp sign-off is not a good-faith exam.
Diligence question. Show the workflow for how a new patient is evaluated before receiving treatment. Who performs the exam? What is documented? What informs the treatment plan?
Diligence signal. “The RN takes the history and the medical director signs off later” is a signal. So is “the patient fills out an intake form and then goes back for treatment.” Asynchronous questionnaire-only intake is a defect the buyer’s post-closing operation cannot simply continue.
Fix path. The MSA and clinical protocols the buyer’s structure adopts need to establish a defensible good-faith exam workflow. This is not just a documentation exercise; it is an operational commitment.
6. Standardized procedures for RN-delegated functions are missing, outdated, or generic
Why it matters. Where an RN performs functions delegated by a physician or NP — injecting Botox or filler, administering IV therapy, performing laser treatment — those functions have to be governed by written standardized procedures developed and reviewed under 16 CCR § 1474. Standardized procedures are practice-specific; a generic PDF from a formation service is not a compliant standardized procedures manual.
Diligence question. Produce the standardized procedures manual for RN-delegated functions. When was it last reviewed and signed by the medical director?
Diligence signal. No manual, an out-of-date manual, or a manual that appears to have been downloaded from a template site is a defect. Standardized procedures for controlled-substance administration are especially important and especially often deficient.
Fix path. The buyer’s structure adopts practice-specific standardized procedures reviewed and signed by the actual medical director and updated on a defined cadence.
7. Fee-splitting or referral arrangements in the MSA or medical director agreement
Why it matters. B&P § 650 prohibits fee-splitting and payments for referrals in California healthcare, with specific carve-outs. § 650(b) permits management fees that reflect fair market value for services furnished, as confirmed in Epic Medical Management, LLC v. Paquette, 244 Cal. App. 4th 504 (2015). MSAs that pay a percentage of gross revenue without FMV support, medical director agreements that pay based on patient volume, or referral relationships with adjacent providers that involve fee-sharing are red flags.
Diligence question. How is the current medical director compensated? How is the current MSO (if any) compensated? Is there any arrangement in which someone receives payment based on referrals or patient volume?
Diligence signal. Percentage-of-revenue MSA fees without FMV documentation. Medical director compensation calibrated to patient throughput. Any explicit or implicit referral-payment relationship with adjacent providers.
Fix path. The buyer’s MSA and medical director agreement are structured with FMV support and no volume-based or referral-based compensation elements. FMV documentation is refreshed annually.
8. Missing or expired Fictitious Name Permit
Why it matters. A medical corporation operating under a name other than the physician’s name plus a corporate designator needs a Fictitious Name Permit from the Medical Board of California under B&P § 2415. Practices that operate under a brand name — nearly all med spas, IV clinics, and specialty practices — need the FNP in place before opening under the brand.
Diligence question. Produce the current Fictitious Name Permit. Confirm the name on the permit matches the name on the practice’s marketing, website, and patient-facing materials.
Diligence signal. No FNP. An FNP for a different name than the one the practice actually uses. An FNP that has expired or was never properly renewed.
Fix path. The new PC applies for and receives its own FNP before closing (or before operating under the brand name post-closing).
9. Direct patient billing by the LLC or non-physician entity
Why it matters. Patient billing statements should come from the professional corporation that rendered the services, not from an entity that could not lawfully render them. Direct billing by an LLC for medical services is one of the specific issues the California AG called out in the Carbon Health settlement, and it can trigger both CPOM exposure and separate consumer-protection / false-advertising exposure.
Diligence question. What name appears on patient billing statements, superbills, and receipts? What entity is on the merchant processing account that receives patient payments?
Diligence signal. The LLC or non-physician entity is on billing statements. The merchant processor is set up under the LLC. Patient credit-card statements show payments to the non-physician entity.
Fix path. Post-closing, all patient billing runs through the PC. The MSO receives its management fee from the PC. Merchant processing and payment infrastructure needs to be reconfigured accordingly.
10. Marketing that overstates provider credentials or misrepresents structure
Why it matters. Marketing that says “our medical team,” “our physician-led practice,” or “our doctors” needs to reflect the actual clinical structure of the practice. Marketing that overstates outcomes, misrepresents in-network insurance status, or implies clinical involvement of physicians who are not actually involved has been a recurring theme in AG enforcement (Aspen Dental and Carbon Health both included false-advertising counts). Marketing exposure is separate from CPOM exposure and can outlast a structural fix.
Diligence question. Review the target’s website, social media, brochures, and paid marketing. Compare the representations about the clinical team to the actual clinical team.
Diligence signal. Photos of physicians who are not on the current staff. Statements about “our board-certified physicians” when there is only a part-time medical director. In-network claims that are not accurate. Before-and-after or outcome claims that overstate typical results.
Fix path. Post-closing marketing is rebuilt from the buyer’s actual clinical structure. Historical marketing exposure remains with the seller and needs to be addressed in the deal documents.
11. Historical regulatory or payor issues the seller has not disclosed
Why it matters. Prior Medical Board complaints against the medical director, prior payor audits, prior patient refund demands, prior consumer complaints to the Attorney General or Department of Consumer Affairs — any of these can constrain what the buyer inherits, particularly if the buyer’s structure keeps continuity of operations or personnel.
Diligence question. Has the target, or any physician associated with the target, been the subject of a Medical Board complaint, a Board of Registered Nursing complaint, a payor audit or recoupment demand, a consumer complaint to a regulator, or a lawsuit? Are there any pending regulatory matters?
Diligence signal. The seller says “no” but provides no supporting documentation. The seller identifies a matter as “already resolved” but does not produce the settlement or closing documentation.
Fix path. Reps and warranties, disclosures, indemnification, and — for material historical exposure — escrow or holdback provisions. The deal documents need to allocate the historical exposure between buyer and seller.
12. Franchise-system or formation-service MSA that has never been reviewed by California-specific counsel
Why it matters. MSAs and formation kits from national franchise systems, out-of-state formation services, or generic template providers are often not designed to survive California’s CPOM analysis under Epic / B&P § 650(b), let alone the specific provisions SB 351 (effective January 1, 2026) voids and the arrangements the AG identified as impermissible in the Carbon Health settlement. Templates that pass in Texas, Florida, or Delaware often fail here.
Diligence question. When was the target’s MSA last reviewed by California-specific counsel? Which provisions were reviewed against SB 351 (contract restrictions on non-competes and non-disparagement) and the Carbon Health settlement benchmarks (no assignable options over PC ownership, no exclusive above-market financing arrangements, no MSO authority over clinician hiring and firing)?
Diligence signal. The MSA came from the franchise system. The MSA has never been reviewed by California counsel. The MSA contains assignable option agreements over the PC’s shares, non-compete or non-disparagement clauses in provider agreements, or MSO authority over clinical staffing and compensation.
Fix path. The buyer’s post-closing MSA is drafted (or the existing MSA rewritten) with California-specific counsel review, calibrated to Epic / B&P § 650(b), SB 351, and the Carbon Health benchmarks. The buyer’s structure discards template arrangements the AG has flagged as problematic.
What to Do With the Diligence Findings
Not every red flag kills a deal. Some — a missing FNP, an outdated standardized procedures manual, an unrepresentative marketing image, are administrative fixes the buyer’s counsel can address in the transition. Others, no physician-owned PC, a paper medical director who has been serving as the only physician of record, direct LLC billing for years, an MSA with the specific arrangements the Carbon Health settlement enjoined, are structural findings that change the deal materially or, in some situations, disqualify the target.
Two general rules apply.
First, catch the red flags before the LOI. Structural findings that would change the price, the structure, or the timing are much easier to negotiate before an LOI has anchored deal terms. Buyers who reserve CPOM diligence for post-LOI often find the seller unwilling to accommodate the structural changes the findings require, and the buyer has already invested time and money in a deal that cannot compliantly close as originally contemplated.
Second, allocate historical exposure in the deal documents. Historical CPOM, marketing, billing, and regulatory exposure needs to be allocated between buyer and seller through reps and warranties, disclosure schedules, indemnification, and (where the exposure is meaningful) escrow or holdback provisions. The buyer’s post-closing structure should be clean; the seller’s pre-closing history should stay with the seller.
When to Bring Counsel Into the Diligence
Before the LOI is signed. One of the highest-leverage moments to have California healthcare counsel involved in a treatment-business acquisition is the pre-LOI structuring conversation, because the LOI drives closing timing and structure and everything downstream. Once the LOI is signed and diligence is compressed, CPOM findings become disruptions rather than architectural inputs.
Bay Legal, PC represents non-licensee buyers of California treatment businesses through pre-LOI structuring, CPOM diligence, deal documentation, and post-closing integration. For guidance on your specific situation, call (650) 668-8000 or schedule a consultation at baylegal.com/contact.
Frequently Asked Questions
How is CPOM diligence different from standard M&A diligence?
Standard M&A diligence covers financials, contracts, employment, tax, IP, and litigation. CPOM diligence covers the specific California constraints on who can own a treatment business, what entity structure the target uses, whether the target’s operating history complies with California licensing law, and whether the target’s MSA, medical director arrangement, standardized procedures, marketing, and billing survive scrutiny. CPOM diligence is where non-licensee buyers most often find defects that standard M&A diligence misses.
Which red flag is the biggest dealbreaker?
Direct patient billing by an LLC or non-physician entity that has been operating for years is often the hardest defect to work around, because it points to both historical CPOM exposure and separate consumer-protection or false-advertising exposure. That said, most defects are fixable if identified before the LOI and addressed in the deal structure. The dealbreaker is not usually any single finding — it is a pattern of findings the seller will not accommodate in the deal terms.
Can I still buy a target that has a paper medical director?
Often, yes — but the buyer’s post-closing structure needs a real, engaged medical director (typically the same physician who holds the PC), and the historical exposure attached to the paper arrangement needs to be allocated to the seller through reps, warranties, indemnification, and where appropriate escrow.
What if the seller refuses to accommodate the structural changes CPOM diligence identifies?
Sellers who will not accommodate the structural changes CPOM diligence identifies are typically either poorly counseled or trying to move historical exposure onto the buyer. In either case, the buyer’s downside on the deal is meaningfully greater than the buyer’s upside. Walking away is a legitimate outcome.
Do I need to be worried about the Carbon Health settlement?
The Carbon Health settlement (June 2026) matters for buyers because it identified specific MSA arrangements the Attorney General considers per se impermissible and imposed a $100,000 civil penalty on a non-licensee co-founder personally. For a non-licensee buyer, the settlement is both a diligence benchmark (check the target’s MSA against the arrangements the AG enjoined) and a personal-exposure signal (individual liability for CPOM violations is now a documented reality, not a theoretical risk).
Talk to a California Healthcare Acquisition Attorney
Bay Legal, PC represents non-licensee buyers of California treatment businesses. For guidance on your specific situation, call (650) 668-8000 or schedule a consultation at baylegal.com/contact.
